Brief: Otsuka Pharmaceutical Announces U.S. FDA Clearance Of Rejoyn
01/04/2024 18:06
April 1 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA PHARMACEUTICAL: U.S. FDA CLEARED REJOYN, FIRST
PRESCRIPTION DIGITAL THERAPEUTIC AUTHORIZED FOR TREATMENT OF
MAJOR DEPRESSIVE DISORDER SYMPTOMS
Further company coverage: 4578.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug